Insilico Medicine’s AI-driven approach yields promising PTPN2/N1 inhibitor for cancer immunotherapy Post author: Post published:April 14, 2024 Post category:uncategorized In recent years, cancer immunotherapy, exemplified by PD-1 and its ligand PD-L1 blockade, has made remarkable advances. You Might Also Like New research links sphingolipids to heart disease and atherosclerosis November 19, 2024 Researchers navigate the intricate ethical landscape of brain organoid studies March 5, 2024 New blood test could be an early warning for child diabetes September 24, 2024